Potential Economic Value of Multi-cancer Early Detection Testing Under Differential Cost Trends for Cancer Screening and Management
Early detection with MCED may help mitigate rising cancer management costs, yielding improved cost-effectiveness and, in some scenarios, a path to cost neutrality.
Authors
- M. Feldman (ORCID: https://orcid.org/0000-0001-5609-1464)
- Ali Tafazzoli (ORCID: https://orcid.org/0000-0003-1874-1467)
- Denise Zou (ORCID: https://orcid.org/0009-0002-5549-7475)
- Walter Morris
- A. Mark Fendrick
- Weicheng Ye
- Bruce Quinn
Institutions
- University of Michigan (US)
- Grail (United States) (US)
- Thermo Fisher Scientific (United States) (US)
- Hematology Oncology Associates (US)
Publication Details
- Journal
- PharmacoEconomics - Open
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1007/s41669-025-00626-7
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00